Final Program

186 MONDAY • MAY 16
P15
P16
P17
P18
P19
P20
P21
P22
P23
P24
Facilitator:
P25
Reductive Stress in Pulmonary Arterial Hypertension/O.
Rafikova, V. Nair, A.A. Desai, S.M. Black, R. Rafikov, Tucson, AZ,
p.A3885
HDAC6-Hsp90: A Shock Duo Implicated in Pulmonary Arterial
Hypertension/S. Chabot, O. Boucherat, G. Ruffenach, S.
Breuils-Bonnet, E. Tremblay, S. Provencher, S. Bonnet, Quebec,
Canada, p.A3886
Isolated Heart Model Demonstrates Evidence of Contractile
and Diastolic Dysfunction in Right Ventricles from Rats with
Sugen/Hypoxia-Induced Pulmonary Hypertension (SuHx-PH)/E.
Nevo-Netes, A. Vayl, A. Frump, J.A. Kline, T. Lahm, Indianapolis,
IN, p.A3887
Evaluation of the Therapeutic Effects of Nitrite and Metformin
in a Mouse Model of Pulmonary Hypertension Associated with
Heart Failure and Preserved Ejection Fraction /Q. Meng, M.
Bueno, N. Kelly, Y.C. Lai, A.L. Mora, M.T. Gladwin, Pittsburgh, PA,
p.A3888
Left Ventricular Function Measured by Speckle-Tracking
Based Strain and Strain Rate Echocardiography in
Experimental Pressure Overload-Induced Right Ventricular
Hypertrophy/B. Kojonazarov, M. Boehm, T. Novoyatleva, C. Lu, F.
Grimminger, N. Weissmann, H.A. Ghofrani, W. Seeger, R.T.
Schermuly, Giessen, Germany, p.A3889
New Mouse Model of Pulmonary Hypertension Induced by
Respiratory Syncytial Virus Bronchiolitis/D. Kimura, J. Saravia,
I. McNamara, R.D. Sullivan, D. You, S.A. Cormier, Memphis, TN,
p.A3890
Carbonic Anhydrase Is Not a Relevant Nitrite Reductase in the
Lung/P.A. Pickerodt, S. Kronfeldt, M. Russ, K. Vorbrodt, P. Lother,
T. Busch, W. Boemke, E.R. Swenson, R.C.E. Francis, Berlin,
Germany, p.A3891
Combination Ambrisentan and Tadalafil Preserve Vascular
Volume Quantified by Micro CT Better than Either
Monotherapy/D. Lachant, D. Haight, S.R. Glickman, S. Akers, R.D.
Ambrosini, S. Staicu, R.J. White, Rochester, NY, p.A3892
Gap Junction Connexin-43 Mislocalization and a-Actinin
Expressional Changes in the Right Ventricle: Potential
Contributors to Right Heart Failure in Pulmonary
Hypertension/O. Lohani, Aurora, CO, p.A3893
Urocortin-2 Improves Right Ventricular Function in Pulmonary
Arterial Hypertension/R. Adao, P. Mendes-Ferreira, D.
Santos-Ribeiro, C. Maia-Rocha, F. Potus, S. Breuils-Bonnet, S.
Provencher, S. Bonnet, A. Leite-Moreira, C. Bras-Silva, Porto,
Portugal, p.A3894
F. Potus, PhD, Quebec, Canada
Using Genetics, Epigenetics and Small Molecules to Reverse
Metabolic Reprogramming in Adventitia Fibroblasts for
Pulmonary Hypertension Therapy/H. Zhang, D. Wang, M. Li, L.
Plecita, A. D’alessandro, S. Riddle, B.A. McKeon, A. Flockton, M.
Frid, P. Petr Jezek, K. El Kasmi, K.R. Stenmark, Aurora, CO,
p.A3895
P26
P27
P28
P29
P30
P31
P32
P33
P34
P35
Facilitator:
P36
Chronic Right Ventricular Pressure Overload May Be
Protective in Patients with Large Acute Pulmonary Emboli/A.S.
Witkin, J. Rodriguez-Lopez, Y. Chang, F. Huang, M. Jaff, B.A.
Parry, K. Rosenfield, R. Rosovsky, R.N. Channick, C. Kabrhel,
Boston, MA, p.A3896
Angiotensin-II (AngII) Induced AngII Type 1 Receptor
Activation Upregulates Alpha-2-Antiplasmin Expression in
Experimental Pulmonary Hypertension Model/S.M. Malik, A.K.
Baidya, V. Chhabra, S.B. Singh, P. Reddy, New Delhi, India,
p.A3897
The Lung Origin of Coronary Artery Diseases in Pulmonary
Hypertension Patients: Role for the DNA damage/BRD4 Axis/J.
Meloche, V. Nadeau, E. Tremblay, F. Potus, S. Chabot, E.
Charbonneau, S. Provencher, S. Bonnet, Quebec City, Canada,
p.A3898
Combination Ambrisentan and Tadalafil Prevents Right
Ventricular Enlargement Better than Either Monotherapy/S.R.
Glickman, D. Lachant, S. Akers, S. Staicu, D. Haight, R.J. White,
Rochester, NY, p.A3899
Distinct Effects of Phosphodiesterase-5 and Fibroblast Growth
Factor Receptor-1 Inhibitors in Monocrotaline-Induced
Pulmonary Arterial Hypertension/N.S. Felix, L. Mendonca, J.S.
Da Silva, C.L. Braga, C.S. Samary, F.F. Cruz, N.N. Rocha, G.
Zapata-Sudo, P.R.M. Rocco, P.L. Silva, Rio de Janeiro, Brazil,
p.A3900
Early Hemodynamic and Echocardiographic Indicators of
Right Ventricular Dysfunction in Neonatal Calves with
Pulmonary Hypertension/R.D. Brown, K.S. Hunter, K. Bartels,
K.R. Stenmark, Aurora, CO, p.A3901
MicroRNA and Gene Dysregulation in Pulmonary
Hypertension: Experimental Findings in a Large Animal Model
Compared to Predictions by a Systems Biology Approach/A.
Rothman, H. Restrepo, V. Sarukhanov, W.N. Evans, R. Williams, K.
Anderson, N. Hamburger, D. Mann, Las Vegas, NV, p.A3902
CARSKNKDC (CAR) Selective Enhancement of
Fasudil-Induced Pulmonary Vasodilation in a Porcine Model of
Chronic Pulmonary Hypertension/A. Rothman, H. Restrepo,
W.N. Evans, V. Sarukhanov, D. Mann, Las Vegas, NV, p.A3903
The Orally Available p110a Selective PI3K Inhibitor BYL719
Reduces Hypoxia-Induced PH in Mice/E.M. Berghausen, A.
Behringer, M. Vantler, S. Baldus, S. Rosenkranz, Cologne,
Germany, p.A3904
Inflammation and Obesity in Fattening Steers at Low
Elevations: A Natural Animal Model of Irreversible Hypoxic
Pulmonary Hypertension, Pulmonary Arterio-Venous
Remodeling, and Heart Failure/G. Krafsur, R.D. Brown, S. Riddle,
M. Frid, J. Poth, D. Gould, J. Neary, T. Holt, F. Garry, K.R.
Stenmark, Aurora, CO, p.A3905
L. Zhao, MD, PhD, London, United Kingdom
Inhibition of Fibrotic and Hypoxia Gene Response in a
Pulmonary Vascular Surrogate System with a Small Molecule
Stimulator of Soluble Guanylate Cyclase/D.P. Zimmer, B.K.
Cole, P. Ge, K. Tang, G.T. Milne, M. Simmers, R. Feaver, M.S.
Collado, S. Hoang, M. Lawson, A. Mackey, D. Manka, B.R.
Blackman, M. Ribadeneira, Cambridge, MA, p.A3906
ATS 2016 • San Francisco